Digital Cognitive Scores May Streamline Alzheimer Disease Biomarker Testing: Daily Dose

Patient Care brings primary care clinicians a lot of medical news every day—it’s easy to miss an important study. The Daily Dose provides a concise summary of one of the website's leading stories you may not have seen.

On March 3, 2026, we reported on data presented at the International Conference on Alzheimer’s and Parkinson’s Diseases and Related Neurological Disorders (AD/PD™ 2026) that focused on multimodal digital assessments designed to support identification of candidates for emerging Alzheimer disease therapies.

The research

Researchers presented 3 posters at AD/PD 2026. Poster #1367 evaluates the use of the Digital Clock and Recall (DCR™), combining the DCR Cognition Score and Amyloid Positivity Risk. The multimodal, machine-learning models demonstrated strong performance in identifying individuals in earlier symptomatic stages, including mild cognitive impairment or mild dementia likely due to Alzheimer disease, who may be appropriate candidates for disease-modifying therapies.

Poster #1925 examined prediction of plasma p-tau217 status and Alzheimer disease risk using the remote-ready Digital Assessment of Cognition (DAC). The approach showed high classification accuracy and negative predictive value as a front-end screener, potentially helping to prioritize confirmatory testing and reduce unnecessary biomarker testing for low-likelihood candidates.

A third poster, presented by Stina Saunders, PhD, Personalized Medicine Lead at Linus Health, reported on feasibility and acceptability of the Electronic Person Specific Outcome Measures (ePSOM) tool in a Japanese memory clinic population (Poster #2179). The study evaluated implementation of culturally responsive, person-specific outcome measures in patients with early symptomatic Alzheimer disease.

Click here for more details.